enabling transformation through science
Parthasarathi BioLab
_edited.jpg)
A Government of India registered Healthcare StartUp
What We Do
We at Parthasarathi BioLab are developing low-cost affordable diagnostic solutions using molecular biology techniques and Artificial Intelligence (AI). We are currently working on multiple innovative projects. After successfully developing one of the first SARS-CoV-2 diagnostic kits in India, we are now working on the detection of a range of pathogens, and some forms of cancer. We are working to develop an entire diagnostic ecosystem that will allow its application in a resource-constrained environment and robust settings. We are also working on AI-based diagnostic solutions for the prediction of abnormalities from physiological signals and diagnostic instruments data. Our experience while working on the SARS-CoV-2 diagnostic solutions has revealed that although a lot of research has been done to improve healthcare technologies in general, it has failed to some extent in translating its impact towards underprivileged people of the society. !! We have decided to change this scenario !!
RESEARCH
About the Parthasarathi BioLab
Flexible AI diagnostic applications
We work on the development of AI-based applications that integrate seamlessly with diagnostic device data such as ECG, Stethoscope, MRI, X-RAY to identify and predict possible abnormalities in the patient. This allows timely intervention by the health professionals thus helping improve the quality of patient care.
Molecular Detection of pathogens
One of our prime projects is the development of an entire ecosystem for reliable, affordable, and high throughput diagnostics for many pathogens. One of the objectives includes the identification of antibiotic resistance among many life-threatening pathogens and several forms of cancer.
Synthetic Biology based Enzyme production
One of the many reasons that diagnostic solutions are still expensive in India is the extreme dependence on the import of many critical enzymes. This is true for many pharmaceutical intermediates and compounds as well. Our fourth phase of the project involves the production of several critical diagnostic enzymes and nutraceuticals.